CAS 847163-28-4

Formel: C15H11N3O

InChl: InChI=1S/C15H11N3O/c1-17-15-13(9-16)18-14(19-15)12-8-4-6-10-5-2-3-7-11(10)12/h2-8,17H,1H3

InChI Key: DYXYXTDIFMDJIR-UHFFFAOYSA-N

SMILES: CNC1=C(N=C(O1)C2=CC=CC3=CC=CC=C32)C#N

ML351

CAS: 847163-28-4

ML351

Formel: C₁₅H₁₁N₃O

Reinheit: ≥95%

Molekulargewicht: 249.27

Ref: 54-BUP07261

ML351

CAS: 847163-28-4

Formel: C₁₅H₁₁N₃O

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 249.2673

Ref: IN-DA00GAOI

ML351

CAS: 847163-28-4

5-(Methylamino)-2-(naphthalen-1-yl)oxazole-4-carbonitrile

Formel: C₁₅H₁₁N₃O

Reinheit: 98%

Molekulargewicht: 249.27

Ref: IN-DG00931567

ML351

CAS: 847163-28-4

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM).

Formel: C₁₅H₁₁N₃O

Reinheit: 97.67%

Farbe und Form: White Solid

Molekulargewicht: 249.2673

Ref: TM-T21902

ML351

CAS: 847163-28-4

ML351 is a resolvin, which are lipid mediators that serve as precursors to other compounds. Resolvins have been shown to be active in the central nervous system and cardiovascular system. ML351 binds to an enzyme that is required for the production of these mediators. This binding prevents the enzyme from converting arachidonic acid into prostaglandin H2, leading to irreversible inhibition of this enzyme. ML351 has been shown to inhibit the inflammatory response in cells by preventing the production of pro-inflammatory molecules such as prostaglandins and platelet-activating factor (PAF). It also has potential drug targets in congestive heart failure, cardiac hypertrophy, and nonsteroidal anti-inflammatory drugs.

Formel: C₁₅H₁₁N₃O

Reinheit: Min. 95%

Molekulargewicht: 249.27 g/mol

Ref: 3D-XIB16328